title: Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
abstract: The development of cardiac-specific adeno-associated viral vectors capable of long-term transgenic expression has opened new avenues in the therapeutic approach to heart failure. Failing cardiomyocytes demonstrate altered calcium-handling secondary to depressed expression and activity of myocardial sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a). This observation has led to a large body of research investigating the therapeutic utility of SERCA2a gene therapy in heart failure.
authors.affiliation: Departments of Medicine, Mount Sinai Medical Center, New York, NY 10595, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Papolos
authors.forename: William H
authors.initials: WH
authors.lastname: Frishman
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D006333:Heart Failure / Q000201:enzymology / Q000628:therapy*; D006801:Humans; D051381:Rats; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D012756:Sheep
chemical_list: D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; C506946:ATP2A2 protein, human